UroGen Pharma Short Interest Ratio and Short Volume

+0.77 (+4.44 %)
(As of 05/11/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,947 shs
Average Volume184,011 shs
Market Capitalization$378.65 million
P/E RatioN/A
Dividend YieldN/A

Short Interest

UroGen Pharma (NASDAQ:URGN) Short Interest Data

Current Short Volume2,370,000 shares
Previous Short Volume2,330,000 shares
Change Vs. Previous Month+1.72%
Dollar Volume Sold Short$41.78 million
Short Interest Ratio / Days to Cover12.0
Last Record DateApril, 15 2021
Outstanding Shares20,790,000 shares
Float Size19,010,000 shares
Short Percent of Float12.47%
Today's Trading Volume3,947 shares
Average Trading Volume184,011 shares
Today's Volume Vs. Average-97.86%

Short Interest Over Time

UroGen Pharma (NASDAQ:URGN) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/15/20212,370,000 shares $41.78 million +1.7%12.5%12$17.63
3/31/20212,330,000 shares $43.15 million -4.9%12.3%11.2$18.52
3/15/20212,450,000 shares $48.00 million -11.2%12.9%11.1$19.59
2/26/20212,760,000 shares $55.89 million +1.5%14.7%13.6$20.25
2/12/20212,720,000 shares $70.94 million +3.8%14.5%14.8$26.08
1/29/20212,620,000 shares $58.61 million -0.8%13.9%14.6$22.37
1/15/20212,640,000 shares $55.26 million -1.9%14.0%15.3$20.93
12/31/20202,690,000 shares $48.66 million +8.9%14.3%17.4$18.09
12/15/20202,470,000 shares $45.97 million -9.5%13.1%17.9$18.61
11/30/20202,730,000 shares $55.97 million +2.6%14.4%21.2$20.50
10/30/20203,010,000 shares $69.20 million -3.8%16.0%20.1$22.99
10/15/20203,130,000 shares $70.77 million -1.6%16.6%20.5$22.61
9/30/20203,180,000 shares $61.34 million -0.6%16.9%20.5$19.29
9/15/20203,200,000 shares $70.43 million +2.9%17.0%20.1$22.01
8/31/20203,110,000 shares $78.03 million -0.6%16.5%19.7$25.09
8/14/20203,130,000 shares $71.83 million +2.3%16.6%21$22.95
7/31/20203,060,000 shares $67.60 million +2.3%17.0%18.9$22.09
7/15/20202,990,000 shares $70.89 million +5.7%16.7%15.8$23.71
6/30/20202,830,000 shares $73.92 million +5.2%15.9%11.7$26.12
6/15/20202,690,000 shares $71.55 million -2.9%15.1%10.6$26.60
5/29/20202,770,000 shares $66.48 million +1.8%16.1%10$24.00
5/15/20202,720,000 shares $67.05 million +3.0%15.8%9.9$24.65
4/30/20202,640,000 shares $64.34 million +3.1%14.2%10.2$24.37
4/15/20202,560,000 shares $53.86 million +10.3%14.9%11$21.04
3/31/20202,320,000 shares $41.39 million +9.1%13.5%11.9$17.84

UroGen Pharma (NASDAQ:URGN) Short Interest FAQ

speech bubbles
speech bubbles

What is UroGen Pharma's current short interest?

Short interest is the volume of UroGen Pharma shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 2,370,000 shares of URGN short. 12.47% of UroGen Pharma's shares are currently sold short. View details.

What is a good short interest ratio for UroGen Pharma?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. UroGen Pharma currently has a short interest ratio of 12.0.

What is a good short interest percentage for UroGen Pharma?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.47% of UroGen Pharma's floating shares are currently sold short.

Is UroGen Pharma's short interest increasing or decreasing?

UroGen Pharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,370,000 shares, an increase of 1.7% from the previous total of 2,330,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is UroGen Pharma's float size?

UroGen Pharma currently has issued a total of 20,897,000 shares. Some of UroGen Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. UroGen Pharma currently has a public float of 19,010,000 shares.

How does UroGen Pharma's short interest compare to its competitors?

12.47% of UroGen Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to UroGen Pharma: Prelude Therapeutics Incorporated (4.12%), Zealand Pharma A/S (0.00%), Kronos Bio, Inc. (11.69%), Y-mAbs Therapeutics, Inc. (10.79%), Zymeworks Inc. (0.00%), COMPASS Pathways plc (5.20%), ImmunoGen, Inc. (0.00%), Aurinia Pharmaceuticals Inc. (7.74%), Theravance Biopharma, Inc. (7.26%), and Protagonist Therapeutics, Inc. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Analog Devices, Inc. ($5.85 billion), Aon plc ($5.61 billion), Charter Communications, Inc. ($5.44 billion), Snap Inc. ($3.49 billion), Airbnb, Inc. ($3.35 billion), Peloton Interactive, Inc. ($2.53 billion), ViacomCBS Inc. ($2.48 billion), Expedia Group, Inc. ($2.39 billion), The Kroger Co. ($2.26 billion), and Nuance Communications, Inc. ($2.18 billion). View all of the most shorted stocks.

What does it mean to sell short UroGen Pharma stock?

Short selling URGN is an investing strategy that aims to generate trading profit from UroGen Pharma as its price is falling. UroGen Pharma's stock is trading up $0.77 today. To short UroGen Pharma stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that UroGen Pharma will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against UroGen Pharma?

A short squeeze for UroGen Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of URGN, which in turn drives the price of the stock up even further.

How often is UroGen Pharma's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including URGN, twice per month. The most recent reporting period available is April, 15 2021.

This page was last updated on 5/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. View terms.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.